Silence Therapeutics (SLN) Current Deferred Revenue: 2019-2025
Historic Current Deferred Revenue for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $301,000.
- Silence Therapeutics' Current Deferred Revenue rose 106.41% to $301,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $301,000, marking a year-over-year increase of 106.41%. This contributed to the annual value of $306,000 for FY2024, which is 95.34% down from last year.
- Silence Therapeutics' Current Deferred Revenue amounted to $301,000 in Q3 2025, which was down 34.14% from $457,000 recorded in Q2 2025.
- Silence Therapeutics' 5-year Current Deferred Revenue high stood at $10.4 million for Q4 2022, and its period low was -$10.0 million during Q1 2023.
- In the last 3 years, Silence Therapeutics' Current Deferred Revenue had a median value of -$3.9 million in 2024 and averaged -$2.7 million.
- In the last 5 years, Silence Therapeutics' Current Deferred Revenue slumped by 1,143.50% in 2023 and then spiked by 111.61% in 2025.
- Over the past 5 years, Silence Therapeutics' Current Deferred Revenue (Quarterly) stood at $5.7 million in 2021, then spiked by 81.60% to $10.4 million in 2022, then plummeted by 36.80% to $6.6 million in 2023, then plummeted by 95.34% to $306,000 in 2024, then soared by 106.41% to $301,000 in 2025.
- Its last three reported values are $301,000 in Q3 2025, $457,000 for Q2 2025, and $392,000 during Q1 2025.